MetaCap

IRulya Therapeutics Quarterly Balance Sheet

NASDAQ: IRLAHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD

39.88-0.06 (-0.15%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

IRulya Therapeutics financial position

As of Sep 30, 2026, IRulya Therapeutics reported total assets of $106.5 million, down 3.1% from a year earlier against total liabilities of $28.4 million. Shareholders' equity was negative at -$65.7 million, meaning liabilities exceed assets; this is often the result of large share buybacks or accumulated losses. The company held $39.8 million in cash and equivalents against $0 of debt, a net cash position of $39.8 million.

The current ratio (current assets divided by current liabilities) was 14.72, meaning short-term assets cover obligations due within a year.

Summary generated from market data by MetaCap's automated system. Methodology

IRulya Therapeutics balance sheet (quarterly)

IRulya Therapeutics quarterly balance sheet
Quarter (USD)Q3 20262026-09-30Q2 20262026-06-30Q1 20262026-03-31Q4 20252025-12-31Q3 20252025-09-30Q2 20252025-06-30Q1 20252025-03-31Q4 20242024-12-31Q3 20242024-09-30Q2 20242024-06-30Q1 20242024-03-31Q4 20232023-12-31
Cash & Equivalents39.82M115.98M18.16M5.81M6.45M16.83M7.77M6.21M2.67M7.89M21.81M20.75M
Short-Term Investments65.42M0011.94M———34.57M45.17M51.55M46.01M54.31M
Total Current Assets106.30M123.41M25.58M22.90M29.20M37.34M33.83M44.04M51.72M63.44M70.44M77.44M
Property, Plant & Equipment69.00K506.00K550.00K595.00K616.00K573.00K448.00K315.00K208.00K246.00K234.00K234.00K
Goodwill————0——00017.25M17.63M
Intangible Assets00067.82M67.73M67.57M62.37M60.05M64.53M61.79M62.25M63.67M
Long-Term Investments———————————0
Total Assets106.47M124.00M26.62M93.52M109.90M117.21M107.09M114.48M126.52M134.83M159.29M167.90M
Accounts Payable1.45M4.64M5.39M2.22M3.40M1.76M3.01M2.90M1.62M2.40M2.07M2.03M
Short-Term Debt00018.03M17.52M——0————
Total Current Liabilities7.22M8.50M8.77M43.23M26.04M7.47M8.36M7.28M5.42M10.32M9.84M9.57M
Long-Term Debt———0016.99M15.27M14.32M14.90M13.83M13.52M13.43M
Total Liabilities28.37M15.51M10.95M129.24M108.84M105.47M88.51M84.33M81.59M87.86M85.11M82.82M
Shareholders' Equity-65.70M-35.32M15.67M-35.71M1.06M11.74M18.58M30.15M44.93M46.97M74.18M85.08M
Retained Earnings-527.77M-500.03M-424.54M-460.45M-420.99M-407.55M-391.50M-376.47M-364.01M-358.52M-330.79M-319.64M
Total Debt00018.03M17.52M16.99M15.27M14.32M14.90M13.83M13.52M13.43M
Net Cash (Debt)105.24M115.98M18.16M-274.00K-11.07M-163.00K-7.50M26.46M32.95M45.61M54.30M61.63M
Shares Outstanding1.02M1.02M13.79M278.63K54.49M53.62M44.09M44.00M43.28M43.28M43.22M42.97M

This table shows 12 quarterly periods of IRulya Therapeutics's balance sheet, from Q3 2026 back to Q4 2023, across 19 line items including cash & equivalents, short-term investments, receivables. Values in USD; B = billions, M = millions. Fiscal periods follow IRLA's reporting calendar. What is a balance sheet?

More financial data